Sign Out
Pregnancy: There is a limited amount of data (less than 300 pregnancy outcomes) from the use of lanreotide in pregnant women.
Studies in animals have shown reproductive toxicity but no evidence of teratogenic effects (see Pharmacology: Toxicology: Preclinical safety data under Actions). The potential risk for humans is unknown.
As a precautionary measure, it is preferable to avoid the use of lanreotide during pregnancy.
Breast-feeding: It is not known whether Somatuline Autogel is excreted in human milk.
A risk to the newborns/infants cannot be excluded.
Somatuline Autogel should not be used during breast-feeding.
Fertility: Reduced fertility was observed in female rats due to the inhibition of GH secretion at doses in excess of those achieved in humans at therapeutic doses.
Continue with Google